Christian Hogg, executive director and CEO of Chi-Med, discusses the company’s rapid development in tandem with the growth of the Chinese pharmaceutical market, brining genuine global pharmaceutical innovation to China, and the state of Hong Kong’s biotech industry.
Hutchison China MedTech (Chi-Med) is entering a very exciting stage of its development. How do you account for its meteoric success so far?
"The China pharmaceutical market – which is where our business really is – has been growing around 15 to 20 percent a year for the last 15 years, slowing only now to a very respectable 10 to 15 percent. Growth is much easier to achieve in that environment compared to a stagnant market like Europe."
